Atossa Genetics
Financials
Estimates*
USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
EBITDA | (7.1m) | (11.4m) | (17.2m) | (11.3m) | (20.5m) | (27.7m) |
Profit | (8.1m) | (11.4m) | (17.2m) | (17.8m) | (20.6m) | (27.0m) |
R&D budget | 2.3m | 4.2m | 6.6m | 6.6m | 9.2m | 15.1m |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | - | ||
N/A | $6.6m | Early VC | |
N/A | N/A | IPO | |
N/A | $1.0m | Post IPO Equity | |
$25.0m | Post IPO Equity | ||
* | N/A | $25.2m | Post IPO Equity |
Total Funding | AUD10.2m |
Related Content
Recent News about Atossa Genetics
EditAtossa Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative medicines to address significant unmet medical needs. The company primarily targets breast cancer and COVID-19, aiming to create effective and affordable treatments. Atossa collaborates with global organizations to advance its programs efficiently and cost-effectively. The business model involves conducting clinical trials to validate the safety and efficacy of its drug candidates, followed by regulatory approval and commercialization. Revenue is generated through product sales, licensing agreements, and partnerships. Key clients include healthcare providers, hospitals, and research institutions. Atossa's market includes the biopharmaceutical and healthcare sectors, with a focus on oncology and infectious diseases.
Keywords: biopharmaceutical, clinical-stage, breast cancer, COVID-19, innovative therapies, drug development, clinical trials, global collaboration, healthcare, oncology.